Ikena Oncology (NASDAQ:IKNA – Get Free Report)‘s stock had its “neutral” rating reissued by research analysts at Wedbush in a research report issued on Thursday,RTT News reports. They currently have a $2.00 target price on the stock. Wedbush’s target price indicates a potential upside of 18.34% from the company’s previous close. Separately, HC Wainwright reaffirmed […]